Search

Your search keyword '"Qin, Yan‐ru"' showing total 245 results
Start Over Author "Qin, Yan‐ru"
245 results on '"Qin, Yan‐ru"'

7. Genome-wide CRISPR/Cas9 screening identifies a targetable MEST-PURA interaction in cancer metastasis

Author

Xu, Wen Wen, primary, Liao, Long, additional, Dai, Wei, additional, Zheng, Can-Can, additional, Tan, Xiang-Peng, additional, He, Yan, additional, Zhang, Qi-Hua, additional, Huang, Zhi-Hao, additional, Chen, Wen-You, additional, Qin, Yan-Ru, additional, Chen, Kui-Sheng, additional, He, Ming-Liang, additional, Law, Simon, additional, Lung, Maria Li, additional, He, Qing-Yu, additional, and Li, Bin, additional

Published
2023
Full Text
View/download PDF

10. Suppl Figure 3 from FSTL1 Promotes Metastasis and Chemoresistance in Esophageal Squamous Cell Carcinoma through NFκB–BMP Signaling Cross-talk

Author

Lau, Marco Chi-Chung, primary, Ng, Kai Yu, primary, Wong, Tin Lok, primary, Tong, Man, primary, Lee, Terence K., primary, Ming, Xiao-Yan, primary, Law, Simon, primary, Lee, Nikki P., primary, Cheung, Annie L., primary, Qin, Yan-Ru, primary, Chan, Kwok Wah, primary, Ning, Wen, primary, Guan, Xin-Yuan, primary, and Ma, Stephanie, primary

Published
2023
Full Text
View/download PDF

11. Suppl Figure 1 from FSTL1 Promotes Metastasis and Chemoresistance in Esophageal Squamous Cell Carcinoma through NFκB–BMP Signaling Cross-talk

Author

Lau, Marco Chi-Chung, primary, Ng, Kai Yu, primary, Wong, Tin Lok, primary, Tong, Man, primary, Lee, Terence K., primary, Ming, Xiao-Yan, primary, Law, Simon, primary, Lee, Nikki P., primary, Cheung, Annie L., primary, Qin, Yan-Ru, primary, Chan, Kwok Wah, primary, Ning, Wen, primary, Guan, Xin-Yuan, primary, and Ma, Stephanie, primary

Published
2023
Full Text
View/download PDF

13. Suppl Figure Legends and Tables from FSTL1 Promotes Metastasis and Chemoresistance in Esophageal Squamous Cell Carcinoma through NFκB–BMP Signaling Cross-talk

Author

Lau, Marco Chi-Chung, primary, Ng, Kai Yu, primary, Wong, Tin Lok, primary, Tong, Man, primary, Lee, Terence K., primary, Ming, Xiao-Yan, primary, Law, Simon, primary, Lee, Nikki P., primary, Cheung, Annie L., primary, Qin, Yan-Ru, primary, Chan, Kwok Wah, primary, Ning, Wen, primary, Guan, Xin-Yuan, primary, and Ma, Stephanie, primary

Published
2023
Full Text
View/download PDF

14. Suppl Figure 5 from FSTL1 Promotes Metastasis and Chemoresistance in Esophageal Squamous Cell Carcinoma through NFκB–BMP Signaling Cross-talk

Author

Lau, Marco Chi-Chung, primary, Ng, Kai Yu, primary, Wong, Tin Lok, primary, Tong, Man, primary, Lee, Terence K., primary, Ming, Xiao-Yan, primary, Law, Simon, primary, Lee, Nikki P., primary, Cheung, Annie L., primary, Qin, Yan-Ru, primary, Chan, Kwok Wah, primary, Ning, Wen, primary, Guan, Xin-Yuan, primary, and Ma, Stephanie, primary

Published
2023
Full Text
View/download PDF

15. Suppl Figure 4 from FSTL1 Promotes Metastasis and Chemoresistance in Esophageal Squamous Cell Carcinoma through NFκB–BMP Signaling Cross-talk

Author

Lau, Marco Chi-Chung, primary, Ng, Kai Yu, primary, Wong, Tin Lok, primary, Tong, Man, primary, Lee, Terence K., primary, Ming, Xiao-Yan, primary, Law, Simon, primary, Lee, Nikki P., primary, Cheung, Annie L., primary, Qin, Yan-Ru, primary, Chan, Kwok Wah, primary, Ning, Wen, primary, Guan, Xin-Yuan, primary, and Ma, Stephanie, primary

Published
2023
Full Text
View/download PDF

16. Data from FSTL1 Promotes Metastasis and Chemoresistance in Esophageal Squamous Cell Carcinoma through NFκB–BMP Signaling Cross-talk

Author

Lau, Marco Chi-Chung, primary, Ng, Kai Yu, primary, Wong, Tin Lok, primary, Tong, Man, primary, Lee, Terence K., primary, Ming, Xiao-Yan, primary, Law, Simon, primary, Lee, Nikki P., primary, Cheung, Annie L., primary, Qin, Yan-Ru, primary, Chan, Kwok Wah, primary, Ning, Wen, primary, Guan, Xin-Yuan, primary, and Ma, Stephanie, primary

Published
2023
Full Text
View/download PDF

17. Suppl Figure 2 from FSTL1 Promotes Metastasis and Chemoresistance in Esophageal Squamous Cell Carcinoma through NFκB–BMP Signaling Cross-talk

Author

Lau, Marco Chi-Chung, primary, Ng, Kai Yu, primary, Wong, Tin Lok, primary, Tong, Man, primary, Lee, Terence K., primary, Ming, Xiao-Yan, primary, Law, Simon, primary, Lee, Nikki P., primary, Cheung, Annie L., primary, Qin, Yan-Ru, primary, Chan, Kwok Wah, primary, Ning, Wen, primary, Guan, Xin-Yuan, primary, and Ma, Stephanie, primary

Published
2023
Full Text
View/download PDF

24. Data from A CD90+ Tumor-Initiating Cell Population with an Aggressive Signature and Metastatic Capacity in Esophageal Cancer

Author

Tang, Kwan Ho, primary, Dai, Yong Dong, primary, Tong, Man, primary, Chan, Yuen Piu, primary, Kwan, Pak Shing, primary, Fu, Li, primary, Qin, Yan Ru, primary, Tsao, Sai Wah, primary, Lung, Hong Lok, primary, Lung, Maria L., primary, Tong, Daniel K., primary, Law, Simon, primary, Chan, Kwok Wah, primary, Ma, Stephanie, primary, and Guan, Xin Yuan, primary

Published
2023
Full Text
View/download PDF

25. Supplementary Methods, Figure Legends, and Tables 1 - 5 from Downregulation of the Novel Tumor Suppressor DIRAS1 Predicts Poor Prognosis in Esophageal Squamous Cell Carcinoma

Author

Zhu, Ying-Hui, primary, Fu, Li, primary, Chen, Leilei, primary, Qin, Yan-Ru, primary, Liu, Haibo, primary, Xie, Fajun, primary, Zeng, Tingting, primary, Dong, Sui-Sui, primary, Li, Jiangchao, primary, Li, Yan, primary, Dai, Yongdong, primary, Xie, Dan, primary, and Guan, Xin-Yuan, primary

Published
2023
Full Text
View/download PDF

28. Supplementary Figure Legend and Table 1 - 5 from A CD90+ Tumor-Initiating Cell Population with an Aggressive Signature and Metastatic Capacity in Esophageal Cancer

Author

Tang, Kwan Ho, primary, Dai, Yong Dong, primary, Tong, Man, primary, Chan, Yuen Piu, primary, Kwan, Pak Shing, primary, Fu, Li, primary, Qin, Yan Ru, primary, Tsao, Sai Wah, primary, Lung, Hong Lok, primary, Lung, Maria L., primary, Tong, Daniel K., primary, Law, Simon, primary, Chan, Kwok Wah, primary, Ma, Stephanie, primary, and Guan, Xin Yuan, primary

Published
2023
Full Text
View/download PDF

37. Supplementary Figure 2 from A CD90+ Tumor-Initiating Cell Population with an Aggressive Signature and Metastatic Capacity in Esophageal Cancer

Author

Tang, Kwan Ho, primary, Dai, Yong Dong, primary, Tong, Man, primary, Chan, Yuen Piu, primary, Kwan, Pak Shing, primary, Fu, Li, primary, Qin, Yan Ru, primary, Tsao, Sai Wah, primary, Lung, Hong Lok, primary, Lung, Maria L., primary, Tong, Daniel K., primary, Law, Simon, primary, Chan, Kwok Wah, primary, Ma, Stephanie, primary, and Guan, Xin Yuan, primary

Published
2023
Full Text
View/download PDF

38. Supplementary Figure 1 from A CD90+ Tumor-Initiating Cell Population with an Aggressive Signature and Metastatic Capacity in Esophageal Cancer

Author

Tang, Kwan Ho, primary, Dai, Yong Dong, primary, Tong, Man, primary, Chan, Yuen Piu, primary, Kwan, Pak Shing, primary, Fu, Li, primary, Qin, Yan Ru, primary, Tsao, Sai Wah, primary, Lung, Hong Lok, primary, Lung, Maria L., primary, Tong, Daniel K., primary, Law, Simon, primary, Chan, Kwok Wah, primary, Ma, Stephanie, primary, and Guan, Xin Yuan, primary

Published
2023
Full Text
View/download PDF

45. Long-term effect of hospital volume on the postoperative prognosis of 158,618 patients with esophageal squamous cell carcinoma in China

Author

Lei, Ling-Ling, primary, Song, Xin, additional, Zhao, Xue-Ke, additional, Xu, Rui-Hua, additional, Wei, Meng-Xia, additional, Sun, Lin, additional, Wang, Pan-Pan, additional, Yang, Miao-Miao, additional, Hu, Jing-Feng, additional, Zhong, Kan, additional, Han, Wen-Li, additional, Han, Xue-Na, additional, Fan, Zong-Min, additional, Wang, Ran, additional, Li, Bei, additional, Zhou, Fu-You, additional, Wang, Xian-Zeng, additional, Zhang, Li-Guo, additional, Bao, Qi-De, additional, Qin, Yan-Ru, additional, Chang, Zhi-Wei, additional, Ku, Jian-Wei, additional, Yang, Hai-Jun, additional, Yuan, Ling, additional, Ren, Jing-Li, additional, Li, Xue-Min, additional, and Wang, Li-Dong, additional

Published
2023
Full Text
View/download PDF

48. Cover Image, Volume 42, Issue 4

Author

Zhu, Xiao‐Dong, Huang, Ming‐Zhu, Wang, Yu‐Sheng, Feng, Wan‐Jing, Chen, Zhi‐Yu, He, Yi‐Fu, Zhang, Xiao‐Wei, Liu, Xin, Wang, Chen‐Chen, Zhang, Wen, Ying, Jie‐Er, Wu, Jun, Yang, Lei, Qin, Yan‐Ru, Luo, Jian‐Feng, Zhao, Xiao‐Ying, Li, Wen‐Hua, Zhang, Zhe, Qiu, Li‐Xin, Geng, Qi‐Rong, Zou, Jian‐Ling, Zhang, Jie‐Yun, Zheng, Hong, Song, Xue‐Feng, Wu, Shu‐Sheng, Zhang, Cheng‐Yan, Gong, Zhe, Liu, Qin‐Qin, Wang, Xiao‐Feng, Xu, Qi, Wang, Qi, Ji, Jian‐Mei, Zhao, Jian, and Guo, Wei‐Jian

Subjects
Cancer Research, Oncology, Additional Covers, humanities
Abstract

The cover image is based on the Original Article XELOX doublet regimen versus EOX triplet regimen as first‐line treatment for advanced gastric cancer: An open‐labeled, multicenter, randomized, prospective phase III trial (EXELOX) by Wei‐Jian Guo et al., https://doi.org/10.1002/cac2.12278. [Image: see text]

Published
2022

49. Health‐related quality of life in stage III‐IV melanoma treated with targeted therapy or immunotherapy: A systematic review on the adequacy of reporting and clinical issues in phase III randomized controlled trials.

Author

Chen, Chen, Wang, Zehua, and Qin, Yan‐Ru

Subjects
QUALITY of life, MELANOMA, IMMUNOTHERAPY
Abstract

Cutaneous melanoma represents around over 90% of all melanoma. With more effective treatments able to extend patients' survival, health‐related quality of life (HRQOL) is increasingly becoming an important endpoint in cancer clinical trials. They are often secondary outcomes measured in phase III randomized controlled trials and their implementation, collection, analysis, and reporting can be challenging methodologically. For these reasons, an increasing number of international recommendations introduced the standards regarding the conduct of HRQOL. In this systematic review, we appraise the adequacy of HRQOL reporting in phase III randomized controlled trials of stage III‐IV cutaneous melanoma and the clinical issues of immunotherapy and small‐molecular‐targeted therapy on HRQOL. Our search strategy totally got 55 articles, and only 13 studies met all inclusion criteria. Findings suggest that most treatments did not yield significant improvements in HRQOL but kept baseline levels, accompanied by prolonged survival and acceptable toxicity. Except for some existing limitations, reporting of HRQOL has made encouraging progress during the period covered by our search, but some aspects still need further optimization. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results